Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
BI 10773 placebo
BI 10773 low dose
BI 10773 high dose
BI 10773 placebo
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria:
- Signed and dated written informed consent by date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation
- Male and female patients with a diagnosis of Type 2 Diabetes Mellitus treated with a stable dose of basal insulin with or without concomitant metformin and / or sulfonylurea.
- Glycosylated hemoglobin A1c (Type A, subtype 1c) of >7.0% and < or = 10% at Visit 1 (screening)
- Suitability for trial participation according to investigator's judgment (evaluating all alternative treatment options and in consideration of the patient completing the study)
- Age > or =18 years at Visit 1 (screening)
- BMI < or = 45 kg/m2 (Body Mass Index) at Visit 1 (screening)
Exclusion criteria:
- Patients with poorly controlled hyperglycemia
- Frequent (at the discretion of the investigator) episodes of hypoglycemic events on basal insulin therapy
- MI, stroke, or TIA within 3 months prior to obtaining informed consent
- Impaired hepatic or renal function; gastric surgery; cancer within the last 5 years; blood dyscrasias
6. Treatment with other anti-diabetics, anti-obesity medications, steroids or thyroid hormones, participation in another trial with an investigational drug 7. Pre-menopausal women on insufficient birth control 8. Alcohol or drug abuse
Sites / Locations
- 1245.33.01014 Boehringer Ingelheim Investigational Site
- 1245.33.01047 Boehringer Ingelheim Investigational Site
- 1245.33.01060 Boehringer Ingelheim Investigational Site
- 1245.33.01013 Boehringer Ingelheim Investigational Site
- 1245.33.01008 Boehringer Ingelheim Investigational Site
- 1245.33.01019 Boehringer Ingelheim Investigational Site
- 1245.33.01055 Boehringer Ingelheim Investigational Site
- 1245.33.01012 Boehringer Ingelheim Investigational Site
- 1245.33.01054 Boehringer Ingelheim Investigational Site
- 1245.33.01046 Boehringer Ingelheim Investigational Site
- 1245.33.01050 Boehringer Ingelheim Investigational Site
- 1245.33.01059 Boehringer Ingelheim Investigational Site
- 1245.33.01028 Boehringer Ingelheim Investigational Site
- 1245.33.01029 Boehringer Ingelheim Investigational Site
- 1245.33.01048 Boehringer Ingelheim Investigational Site
- 1245.33.01033 Boehringer Ingelheim Investigational Site
- 1245.33.01027 Boehringer Ingelheim Investigational Site
- 1245.33.01040 Boehringer Ingelheim Investigational Site
- 1245.33.01062 Boehringer Ingelheim Investigational Site
- 1245.33.01020 Boehringer Ingelheim Investigational Site
- 1245.33.01044 Boehringer Ingelheim Investigational Site
- 1245.33.01024 Boehringer Ingelheim Investigational Site
- 1245.33.01022 Boehringer Ingelheim Investigational Site
- 1245.33.01056 Boehringer Ingelheim Investigational Site
- 1245.33.01032 Boehringer Ingelheim Investigational Site
- 1245.33.01017 Boehringer Ingelheim Investigational Site
- 1245.33.01043 Boehringer Ingelheim Investigational Site
- 1245.33.01051 Boehringer Ingelheim Investigational Site
- 1245.33.01007 Boehringer Ingelheim Investigational Site
- 1245.33.01003 Boehringer Ingelheim Investigational Site
- 1245.33.01016 Boehringer Ingelheim Investigational Site
- 1245.33.01005 Boehringer Ingelheim Investigational Site
- 1245.33.01038 Boehringer Ingelheim Investigational Site
- 1245.33.01026 Boehringer Ingelheim Investigational Site
- 1245.33.01025 Boehringer Ingelheim Investigational Site
- 1245.33.01001 Boehringer Ingelheim Investigational Site
- 1245.33.01031 Boehringer Ingelheim Investigational Site
- 1245.33.01045 Boehringer Ingelheim Investigational Site
- 1245.33.01018 Boehringer Ingelheim Investigational Site
- 1245.33.01041 Boehringer Ingelheim Investigational Site
- 1245.33.01042 Boehringer Ingelheim Investigational Site
- 1245.33.01004 Boehringer Ingelheim Investigational Site
- 1245.33.01036 Boehringer Ingelheim Investigational Site
- 1245.33.01035 Boehringer Ingelheim Investigational Site
- 1245.33.01058 Boehringer Ingelheim Investigational Site
- 1245.33.01037 Boehringer Ingelheim Investigational Site
- 1245.33.01023 Boehringer Ingelheim Investigational Site
- 1245.33.01030 Boehringer Ingelheim Investigational Site
- 1245.33.01006 Boehringer Ingelheim Investigational Site
- 1245.33.01011 Boehringer Ingelheim Investigational Site
- 1245.33.01002 Boehringer Ingelheim Investigational Site
- 1245.33.01049 Boehringer Ingelheim Investigational Site
- 1245.33.01015 Boehringer Ingelheim Investigational Site
- 1245.33.01009 Boehringer Ingelheim Investigational Site
- 1245.33.01010 Boehringer Ingelheim Investigational Site
- 1245.33.01061 Boehringer Ingelheim Investigational Site
- 1245.33.45006 Boehringer Ingelheim Investigational Site
- 1245.33.45001 Boehringer Ingelheim Investigational Site
- 1245.33.45011 Boehringer Ingelheim Investigational Site
- 1245.33.45013 Boehringer Ingelheim Investigational Site
- 1245.33.45004 Boehringer Ingelheim Investigational Site
- 1245.33.45008 Boehringer Ingelheim Investigational Site
- 1245.33.45002 Boehringer Ingelheim Investigational Site
- 1245.33.45003 Boehringer Ingelheim Investigational Site
- 1245.33.3301A Boehringer Ingelheim Investigational Site
- 1245.33.3302A Boehringer Ingelheim Investigational Site
- 1245.33.3305A Boehringer Ingelheim Investigational Site
- 1245.33.3306A Boehringer Ingelheim Investigational Site
- 1245.33.3308A Boehringer Ingelheim Investigational Site
- 1245.33.3309A Boehringer Ingelheim Investigational Site
- 1245.33.3310A Boehringer Ingelheim Investigational Site
- 1245.33.3304A Boehringer Ingelheim Investigational Site
- 1245.33.3303A Boehringer Ingelheim Investigational Site
- 1245.33.35302 Boehringer Ingelheim Investigational Site
- 1245.33.35303 Boehringer Ingelheim Investigational Site
- 1245.33.35304 Boehringer Ingelheim Investigational Site
- 1245.33.82008 Boehringer Ingelheim Investigational Site
- 1245.33.82007 Boehringer Ingelheim Investigational Site
- 1245.33.82001 Boehringer Ingelheim Investigational Site
- 1245.33.82003 Boehringer Ingelheim Investigational Site
- 1245.33.82004 Boehringer Ingelheim Investigational Site
- 1245.33.82005 Boehringer Ingelheim Investigational Site
- 1245.33.82006 Boehringer Ingelheim Investigational Site
- 1245.33.82002 Boehringer Ingelheim Investigational Site
- 1245.33.35104 Boehringer Ingelheim Investigational Site
- 1245.33.35101 Boehringer Ingelheim Investigational Site
- 1245.33.35102 Boehringer Ingelheim Investigational Site
- 1245.33.35106 Boehringer Ingelheim Investigational Site
- 1245.33.35107 Boehringer Ingelheim Investigational Site
- 1245.33.44001 Boehringer Ingelheim Investigational Site
- 1245.33.44003 Boehringer Ingelheim Investigational Site
- 1245.33.44006 Boehringer Ingelheim Investigational Site
- 1245.33.44005 Boehringer Ingelheim Investigational Site
- 1245.33.44009 Boehringer Ingelheim Investigational Site
- 1245.33.44008 Boehringer Ingelheim Investigational Site
- 1245.33.44004 Boehringer Ingelheim Investigational Site
- 1245.33.44007 Boehringer Ingelheim Investigational Site
- 1245.33.44002 Boehringer Ingelheim Investigational Site
- 1245.33.44010 Boehringer Ingelheim Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
BI 10773 low dose
BI 10773 high dose
placebo
Arm Description
Patients receive BI 10773 low dose daily
Patients receive BI 10773 high dose daily
Patients receive placebo to match BI 10773 daily
Outcomes
Primary Outcome Measures
Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 18 Weeks of Treatment
Change from baseline in Glycosylated haemoglobin A1c (HbA1c) after 18 weeks of treatment
Secondary Outcome Measures
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5%) After 18, 54 and 78 Weeks of Treatment
Patients that had a reduction in HbA1c of at least 0.5% from baseline to 18, 54 and 78 weeks of treatment
Change From Baseline in Fasting Plasma Glucose (FPG) After 18, 54 and 78 Weeks of Treatment
Change from baseline in fasting plasma glucose (FPG) after 18, 54 and 78 weeks of treatment
Percent Change From Baseline in Fasting Plasma Glucose (FPG) After 18, 54 and 78 Weeks of Treatment
Percent change from baseline in fasting plasma glucose (FPG) after 18, 54 and 78 weeks of treatment
Change From Baseline in Basal Insulin Dose/Day After 54 and 78 Weeks of Treatment
Change from baseline in basal insulin dose/day after 54 and 78 weeks of treatment
Change From Baseline in Body Weight After 18, 54 and 78 Weeks of Treatment
Change from baseline in body weight after 18, 54 and 78 weeks of treatment
Change From Baseline in Body Weight at Follow-up
Change from baseline in body weight at follow up (82 weeks)
Change From Baseline in HbA1c After 54 and 78 Weeks of Treatment
Change from baseline in HbA1c after 54 and 78 weeks of treatment
The Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 18, 54, and 78 Weeks of Treatment
The occurrence of treat to target efficacy response, that is an HbA1c under treatment of <7.0% After 18, 54, and 78 weeks of treatment
Full Information
NCT ID
NCT01011868
First Posted
November 10, 2009
Last Updated
September 24, 2014
Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
1. Study Identification
Unique Protocol Identification Number
NCT01011868
Brief Title
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
Official Title
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Safety and Efficacy Study of BI 10773 (10 mg and 25 mg) Administered Orally, Once Daily Over 78 Weeks in Type 2 Diabetic Patients Receiving Treatment With Basal Insulin (Glargine, Detemir, or NPH Insulin Only) With or Without Concomitant Metformin and/or Sulfonylurea Therapy and Insufficient Glycemic Control
Study Type
Interventional
2. Study Status
Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
May 2012 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
4. Oversight
5. Study Description
Brief Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
494 (Actual)
8. Arms, Groups, and Interventions
Arm Title
BI 10773 low dose
Arm Type
Experimental
Arm Description
Patients receive BI 10773 low dose daily
Arm Title
BI 10773 high dose
Arm Type
Experimental
Arm Description
Patients receive BI 10773 high dose daily
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Patients receive placebo to match BI 10773 daily
Intervention Type
Drug
Intervention Name(s)
BI 10773 placebo
Intervention Description
BI 10773 placebo
Intervention Type
Drug
Intervention Name(s)
BI 10773 low dose
Intervention Description
BI 10773 low dose
Intervention Type
Drug
Intervention Name(s)
BI 10773 high dose
Intervention Description
BI 10773 high dose
Intervention Type
Drug
Intervention Name(s)
BI 10773 placebo
Intervention Description
BI 10773 placebo
Primary Outcome Measure Information:
Title
Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 18 Weeks of Treatment
Description
Change from baseline in Glycosylated haemoglobin A1c (HbA1c) after 18 weeks of treatment
Time Frame
Baseline and 18 weeks
Secondary Outcome Measure Information:
Title
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5%) After 18, 54 and 78 Weeks of Treatment
Description
Patients that had a reduction in HbA1c of at least 0.5% from baseline to 18, 54 and 78 weeks of treatment
Time Frame
Baseline and 18, 54 and 78 weeks
Title
Change From Baseline in Fasting Plasma Glucose (FPG) After 18, 54 and 78 Weeks of Treatment
Description
Change from baseline in fasting plasma glucose (FPG) after 18, 54 and 78 weeks of treatment
Time Frame
Baseline, 18, 54 and 78 weeks
Title
Percent Change From Baseline in Fasting Plasma Glucose (FPG) After 18, 54 and 78 Weeks of Treatment
Description
Percent change from baseline in fasting plasma glucose (FPG) after 18, 54 and 78 weeks of treatment
Time Frame
Baseline, 18, 54 and 78 weeks
Title
Change From Baseline in Basal Insulin Dose/Day After 54 and 78 Weeks of Treatment
Description
Change from baseline in basal insulin dose/day after 54 and 78 weeks of treatment
Time Frame
Baseline, 54 and 78 weeks
Title
Change From Baseline in Body Weight After 18, 54 and 78 Weeks of Treatment
Description
Change from baseline in body weight after 18, 54 and 78 weeks of treatment
Time Frame
Baseline, 18, 54, 78 weeks
Title
Change From Baseline in Body Weight at Follow-up
Description
Change from baseline in body weight at follow up (82 weeks)
Time Frame
Baseline and 82 weeks
Title
Change From Baseline in HbA1c After 54 and 78 Weeks of Treatment
Description
Change from baseline in HbA1c after 54 and 78 weeks of treatment
Time Frame
Baseline, 54 and 78 weeks
Title
The Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 18, 54, and 78 Weeks of Treatment
Description
The occurrence of treat to target efficacy response, that is an HbA1c under treatment of <7.0% After 18, 54, and 78 weeks of treatment
Time Frame
Baseline, 18, 54 and 78 weeks
Other Pre-specified Outcome Measures:
Title
Confirmed Hypoglycemic Events
Description
Confirmed hypoglycemic events refer to all hypoglycemic events that had a glucose value ≤70 ml/dL or where assistance was required. Symptomatic hypoglycemic events were to be reported as adverse events. Investigator-defined hypoglycaemia adverse events include all events that investigator marked as 'Hypoglycaemic event' in CRFs, regardless of the reported term or blood glucose value. It may include hypoglycemia itself as reported term or any other symptoms that that investigator may have attributed to hypoglycemia (e.g. dizziness, hyperhidrosis, and asthenia).
Time Frame
During the course of the study (82 weeks)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Signed and dated written informed consent by date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation
Male and female patients with a diagnosis of Type 2 Diabetes Mellitus treated with a stable dose of basal insulin with or without concomitant metformin and / or sulfonylurea.
Glycosylated hemoglobin A1c (Type A, subtype 1c) of >7.0% and < or = 10% at Visit 1 (screening)
Suitability for trial participation according to investigator's judgment (evaluating all alternative treatment options and in consideration of the patient completing the study)
Age > or =18 years at Visit 1 (screening)
BMI < or = 45 kg/m2 (Body Mass Index) at Visit 1 (screening)
Exclusion criteria:
Patients with poorly controlled hyperglycemia
Frequent (at the discretion of the investigator) episodes of hypoglycemic events on basal insulin therapy
MI, stroke, or TIA within 3 months prior to obtaining informed consent
Impaired hepatic or renal function; gastric surgery; cancer within the last 5 years; blood dyscrasias
6. Treatment with other anti-diabetics, anti-obesity medications, steroids or thyroid hormones, participation in another trial with an investigational drug 7. Pre-menopausal women on insufficient birth control 8. Alcohol or drug abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1245.33.01014 Boehringer Ingelheim Investigational Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
1245.33.01047 Boehringer Ingelheim Investigational Site
City
Phoenix
State/Province
Arizona
Country
United States
Facility Name
1245.33.01060 Boehringer Ingelheim Investigational Site
City
Fresno
State/Province
California
Country
United States
Facility Name
1245.33.01013 Boehringer Ingelheim Investigational Site
City
Los Angeles
State/Province
California
Country
United States
Facility Name
1245.33.01008 Boehringer Ingelheim Investigational Site
City
Los Gatos
State/Province
California
Country
United States
Facility Name
1245.33.01019 Boehringer Ingelheim Investigational Site
City
National City
State/Province
California
Country
United States
Facility Name
1245.33.01055 Boehringer Ingelheim Investigational Site
City
Paramount
State/Province
California
Country
United States
Facility Name
1245.33.01012 Boehringer Ingelheim Investigational Site
City
Santa Ana
State/Province
California
Country
United States
Facility Name
1245.33.01054 Boehringer Ingelheim Investigational Site
City
Denver
State/Province
Colorado
Country
United States
Facility Name
1245.33.01046 Boehringer Ingelheim Investigational Site
City
Bradednton
State/Province
Florida
Country
United States
Facility Name
1245.33.01050 Boehringer Ingelheim Investigational Site
City
Brooksville
State/Province
Florida
Country
United States
Facility Name
1245.33.01059 Boehringer Ingelheim Investigational Site
City
Chiefland
State/Province
Florida
Country
United States
Facility Name
1245.33.01028 Boehringer Ingelheim Investigational Site
City
Clearwater
State/Province
Florida
Country
United States
Facility Name
1245.33.01029 Boehringer Ingelheim Investigational Site
City
Fleming Island
State/Province
Florida
Country
United States
Facility Name
1245.33.01048 Boehringer Ingelheim Investigational Site
City
Hollywood
State/Province
Florida
Country
United States
Facility Name
1245.33.01033 Boehringer Ingelheim Investigational Site
City
New Port Richey
State/Province
Florida
Country
United States
Facility Name
1245.33.01027 Boehringer Ingelheim Investigational Site
City
Atlanta
State/Province
Georgia
Country
United States
Facility Name
1245.33.01040 Boehringer Ingelheim Investigational Site
City
Decatur
State/Province
Georgia
Country
United States
Facility Name
1245.33.01062 Boehringer Ingelheim Investigational Site
City
Lawrenceville
State/Province
Georgia
Country
United States
Facility Name
1245.33.01020 Boehringer Ingelheim Investigational Site
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
1245.33.01044 Boehringer Ingelheim Investigational Site
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
1245.33.01024 Boehringer Ingelheim Investigational Site
City
Des Moines
State/Province
Iowa
Country
United States
Facility Name
1245.33.01022 Boehringer Ingelheim Investigational Site
City
St. Louis
State/Province
Maryland
Country
United States
Facility Name
1245.33.01056 Boehringer Ingelheim Investigational Site
City
Olive Branch
State/Province
Mississippi
Country
United States
Facility Name
1245.33.01032 Boehringer Ingelheim Investigational Site
City
Kansas City
State/Province
Missouri
Country
United States
Facility Name
1245.33.01017 Boehringer Ingelheim Investigational Site
City
Omaha
State/Province
Nebraska
Country
United States
Facility Name
1245.33.01043 Boehringer Ingelheim Investigational Site
City
Las Vegas
State/Province
Nevada
Country
United States
Facility Name
1245.33.01051 Boehringer Ingelheim Investigational Site
City
New Hartford
State/Province
New York
Country
United States
Facility Name
1245.33.01007 Boehringer Ingelheim Investigational Site
City
Greensboro
State/Province
North Carolina
Country
United States
Facility Name
1245.33.01003 Boehringer Ingelheim Investigational Site
City
Jacksonville
State/Province
North Carolina
Country
United States
Facility Name
1245.33.01016 Boehringer Ingelheim Investigational Site
City
Salisbury
State/Province
North Carolina
Country
United States
Facility Name
1245.33.01005 Boehringer Ingelheim Investigational Site
City
Statesville
State/Province
North Carolina
Country
United States
Facility Name
1245.33.01038 Boehringer Ingelheim Investigational Site
City
Wilmington
State/Province
North Carolina
Country
United States
Facility Name
1245.33.01026 Boehringer Ingelheim Investigational Site
City
Winston-Salem
State/Province
North Carolina
Country
United States
Facility Name
1245.33.01025 Boehringer Ingelheim Investigational Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
1245.33.01001 Boehringer Ingelheim Investigational Site
City
Columbus
State/Province
Ohio
Country
United States
Facility Name
1245.33.01031 Boehringer Ingelheim Investigational Site
City
Tulsa
State/Province
Oklahoma
Country
United States
Facility Name
1245.33.01045 Boehringer Ingelheim Investigational Site
City
Eugene
State/Province
Oregon
Country
United States
Facility Name
1245.33.01018 Boehringer Ingelheim Investigational Site
City
Altoona
State/Province
Pennsylvania
Country
United States
Facility Name
1245.33.01041 Boehringer Ingelheim Investigational Site
City
Carlisle
State/Province
Pennsylvania
Country
United States
Facility Name
1245.33.01042 Boehringer Ingelheim Investigational Site
City
Landsdale
State/Province
Pennsylvania
Country
United States
Facility Name
1245.33.01004 Boehringer Ingelheim Investigational Site
City
Greer
State/Province
South Carolina
Country
United States
Facility Name
1245.33.01036 Boehringer Ingelheim Investigational Site
City
Mt. Pleasant
State/Province
South Carolina
Country
United States
Facility Name
1245.33.01035 Boehringer Ingelheim Investigational Site
City
Seneca
State/Province
South Carolina
Country
United States
Facility Name
1245.33.01058 Boehringer Ingelheim Investigational Site
City
Kingsport
State/Province
Tennessee
Country
United States
Facility Name
1245.33.01037 Boehringer Ingelheim Investigational Site
City
Memphis
State/Province
Tennessee
Country
United States
Facility Name
1245.33.01023 Boehringer Ingelheim Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
1245.33.01030 Boehringer Ingelheim Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
1245.33.01006 Boehringer Ingelheim Investigational Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
1245.33.01011 Boehringer Ingelheim Investigational Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
1245.33.01002 Boehringer Ingelheim Investigational Site
City
Sugar Land
State/Province
Texas
Country
United States
Facility Name
1245.33.01049 Boehringer Ingelheim Investigational Site
City
Salt Lake City
State/Province
Utah
Country
United States
Facility Name
1245.33.01015 Boehringer Ingelheim Investigational Site
City
Norfolk
State/Province
Virginia
Country
United States
Facility Name
1245.33.01009 Boehringer Ingelheim Investigational Site
City
Richmond
State/Province
Virginia
Country
United States
Facility Name
1245.33.01010 Boehringer Ingelheim Investigational Site
City
Federal Way
State/Province
Washington
Country
United States
Facility Name
1245.33.01061 Boehringer Ingelheim Investigational Site
City
Milwaukee
State/Province
Wisconsin
Country
United States
Facility Name
1245.33.45006 Boehringer Ingelheim Investigational Site
City
Aalborg
Country
Denmark
Facility Name
1245.33.45001 Boehringer Ingelheim Investigational Site
City
Aarhus C
Country
Denmark
Facility Name
1245.33.45011 Boehringer Ingelheim Investigational Site
City
Aarhus C
Country
Denmark
Facility Name
1245.33.45013 Boehringer Ingelheim Investigational Site
City
Aarhus C
Country
Denmark
Facility Name
1245.33.45004 Boehringer Ingelheim Investigational Site
City
Gentofte
Country
Denmark
Facility Name
1245.33.45008 Boehringer Ingelheim Investigational Site
City
Hillerød
Country
Denmark
Facility Name
1245.33.45002 Boehringer Ingelheim Investigational Site
City
Hvidovre
Country
Denmark
Facility Name
1245.33.45003 Boehringer Ingelheim Investigational Site
City
København NV
Country
Denmark
Facility Name
1245.33.3301A Boehringer Ingelheim Investigational Site
City
Bondy Cedex
Country
France
Facility Name
1245.33.3302A Boehringer Ingelheim Investigational Site
City
Corbeil Essonnes
Country
France
Facility Name
1245.33.3305A Boehringer Ingelheim Investigational Site
City
La Rochelle Cedex 1
Country
France
Facility Name
1245.33.3306A Boehringer Ingelheim Investigational Site
City
Marseille
Country
France
Facility Name
1245.33.3308A Boehringer Ingelheim Investigational Site
City
Montbrison
Country
France
Facility Name
1245.33.3309A Boehringer Ingelheim Investigational Site
City
Nanterre Cedex
Country
France
Facility Name
1245.33.3310A Boehringer Ingelheim Investigational Site
City
Nantes
Country
France
Facility Name
1245.33.3304A Boehringer Ingelheim Investigational Site
City
Narbonne Cedex
Country
France
Facility Name
1245.33.3303A Boehringer Ingelheim Investigational Site
City
Saint Mandé
Country
France
Facility Name
1245.33.35302 Boehringer Ingelheim Investigational Site
City
Dublin
Country
Ireland
Facility Name
1245.33.35303 Boehringer Ingelheim Investigational Site
City
Dublin
Country
Ireland
Facility Name
1245.33.35304 Boehringer Ingelheim Investigational Site
City
Dublin
Country
Ireland
Facility Name
1245.33.82008 Boehringer Ingelheim Investigational Site
City
Daejeon
Country
Korea, Republic of
Facility Name
1245.33.82007 Boehringer Ingelheim Investigational Site
City
Gwangju
Country
Korea, Republic of
Facility Name
1245.33.82001 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1245.33.82003 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1245.33.82004 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1245.33.82005 Boehringer Ingelheim Investigational Site
City
Seoul
Country
Korea, Republic of
Facility Name
1245.33.82006 Boehringer Ingelheim Investigational Site
City
Wonju
Country
Korea, Republic of
Facility Name
1245.33.82002 Boehringer Ingelheim Investigational Site
City
Yangsan
Country
Korea, Republic of
Facility Name
1245.33.35104 Boehringer Ingelheim Investigational Site
City
Aveiro
Country
Portugal
Facility Name
1245.33.35101 Boehringer Ingelheim Investigational Site
City
Coimbra
Country
Portugal
Facility Name
1245.33.35102 Boehringer Ingelheim Investigational Site
City
Lisboa
Country
Portugal
Facility Name
1245.33.35106 Boehringer Ingelheim Investigational Site
City
Lisboa
Country
Portugal
Facility Name
1245.33.35107 Boehringer Ingelheim Investigational Site
City
Lisboa
Country
Portugal
Facility Name
1245.33.44001 Boehringer Ingelheim Investigational Site
City
Bath
Country
United Kingdom
Facility Name
1245.33.44003 Boehringer Ingelheim Investigational Site
City
Birmingham
Country
United Kingdom
Facility Name
1245.33.44006 Boehringer Ingelheim Investigational Site
City
Blackburn
Country
United Kingdom
Facility Name
1245.33.44005 Boehringer Ingelheim Investigational Site
City
Dorking
Country
United Kingdom
Facility Name
1245.33.44009 Boehringer Ingelheim Investigational Site
City
Headington
Country
United Kingdom
Facility Name
1245.33.44008 Boehringer Ingelheim Investigational Site
City
Leicester
Country
United Kingdom
Facility Name
1245.33.44004 Boehringer Ingelheim Investigational Site
City
Liverpool
Country
United Kingdom
Facility Name
1245.33.44007 Boehringer Ingelheim Investigational Site
City
Wembley
Country
United Kingdom
Facility Name
1245.33.44002 Boehringer Ingelheim Investigational Site
City
Whitstable
Country
United Kingdom
Facility Name
1245.33.44010 Boehringer Ingelheim Investigational Site
City
Wymondham
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
35472672
Citation
Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1245/1245.33_U12-3817-01-DS.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1245/1245.33_Literature.pdf
Description
Related Info
Learn more about this trial
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs